Principal Financial Group Inc. Has $488,000 Stake in Simulations Plus, Inc. $SLP

Principal Financial Group Inc. reduced its holdings in Simulations Plus, Inc. (NASDAQ:SLP) by 64.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,399 shares of the technology company’s stock after selling 58,713 shares during the quarter. Principal Financial Group Inc. owned 0.16% of Simulations Plus worth $488,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Raymond James Financial Inc. bought a new stake in Simulations Plus during the 2nd quarter worth approximately $25,000. CWM LLC boosted its holdings in shares of Simulations Plus by 3,729.1% in the third quarter. CWM LLC now owns 2,106 shares of the technology company’s stock valued at $32,000 after buying an additional 2,051 shares during the period. Farther Finance Advisors LLC acquired a new position in shares of Simulations Plus in the third quarter valued at approximately $40,000. AlphaQuest LLC bought a new stake in shares of Simulations Plus during the second quarter worth $69,000. Finally, State of Tennessee Department of Treasury raised its holdings in shares of Simulations Plus by 182.9% during the second quarter. State of Tennessee Department of Treasury now owns 11,191 shares of the technology company’s stock worth $195,000 after acquiring an additional 7,235 shares during the period. Institutional investors own 78.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on SLP shares. TD Cowen reaffirmed a “hold” rating on shares of Simulations Plus in a research note on Thursday, January 8th. Zacks Research cut Simulations Plus from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 2nd. BTIG Research lowered Simulations Plus from a “buy” rating to a “neutral” rating in a research report on Thursday, December 18th. Citigroup reaffirmed a “market perform” rating on shares of Simulations Plus in a research report on Tuesday, January 6th. Finally, KeyCorp reaffirmed a “sector weight” rating on shares of Simulations Plus in a research note on Wednesday, October 29th. Three analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Simulations Plus presently has an average rating of “Hold” and an average price target of $25.00.

Simulations Plus Stock Performance

Simulations Plus stock opened at $12.21 on Friday. The stock has a 50-day simple moving average of $17.60 and a 200 day simple moving average of $16.52. The stock has a market capitalization of $246.03 million, a P/E ratio of -3.82 and a beta of 1.12. Simulations Plus, Inc. has a 52 week low of $11.60 and a 52 week high of $36.45.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings data on Thursday, January 8th. The technology company reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.05). Simulations Plus had a negative net margin of 81.66% and a positive return on equity of 14.02%. The business had revenue of $18.42 million during the quarter, compared to analyst estimates of $18.05 million. During the same period in the previous year, the business earned $0.17 earnings per share. Research analysts forecast that Simulations Plus, Inc. will post 1.09 earnings per share for the current year.

Simulations Plus Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.